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Pancreatic cancer is a rapidly fatal disease, with a 5-year survival
rate of less than 5% (Kelly and Benjamin, 1995). Surgery has been
considered the only curative modality for this disease, even if at the
time of diagnosis the majority of patients have locally advanced
unresectable or metastatic disease (Casper and Kelsen, 1995). Until
very recently, chemotherapy was held to be largely ineffective in
terms of objective responses, survival or quality of life in advanced
pancreatic cancer patients. Editorials and reviews called repeti-
tively for abandonment of chemotherapy because no clear benefit
was evident (Taylor, 1993; Lionetto et al, 1995). However, in the
last 2 years, opinions about the value of chemotherapy in advanced
pancreatic cancer have varied. Several trials have shown that
chemotherapy can prolong survival and improve quality of life in
advanced pancreatic cancer (Palmer et al, 1994; Andr￿ et al, 1996;
Glimelius et al, 1996; Rothenberg et al, 1996; Burris et al, 1997).
Recently, more aggressive chemotherapy regimens have been
reported to be highly effective in advanced gastric cancer (Cocconi et
al, 1994; Webb et al, 1997). In our multi-institutional trial, a weekly
low dose of cisplatin (CDDP), epidoxorubicin (epi-ADR), leucov-
orin (LV) and 5-fluorouracil (5-FU) determined a high response rate
(62%) and an interesting median survival (11.7 months) in 105
advanced gastric cancer patients (Cascinu et al, 1997). On the basis
of these results, and of the favourable results obtained by
chemotherapy in recent studies, we considered this weekly regimen
worthy of evaluation in the management of patients with advanced
carcinoma of the pancreas.
PATIENTS AND METHODS
Patient selection
Patients with histologically verified locally advanced unresectable
and/or metastatic pancreatic carcinoma were eligible for the study.
Patients thought to have potentially curable disease by resection of
the primary were not eligible. Other eligibility criteria included
performance status Eastern Cooperative Oncology Group grade
0—3, age less than 70 years, and normal liver (serum bilirubin
<1.5 mg dl—1), renal (serum creatinine <1.5 mg dl—1) and bone
marrow (leucocyte count >4000 ml—1, platelet count >100 000 ml—1)
functions. Because epi-ADR was included in the treatment plan,
patients had to have a New York Heart Association class of †2; if
there was a history of cardiac disease, a cardiac-gated pool scan
with an ejection fraction of >45% was required.
Patients were excluded if they had previously undergone
chemotherapy. Patients who had had radiotherapy to individual
sites of disease were eligible, but that (those) site(s) of disease was
(were) considered non-evaluable for response.
Informed consent was obtained from all participants after the
nature of the study had been fully explained, and the protocol was
approved by the institutional review board.
Intensive weekly chemotherapy is not effective in
advanced pancreatic cancer patients: a report from the
Italian Group for the Study of Digestive Tract Cancer
(GISCAD)
S Cascinu, L Frontini, G Comella, S Barni, R Labianca, N Battelli, R Casaretti, S Zonato, M Pirovano, G Catalano and
R Cellerino
Departments and Units of Medical Oncology, Ancona, Naples, Milan, Monza, Pesaro, Italy
Summary Twenty-two patients, with locally advanced unresectable and/or metastatic pancreatic carcinoma, received weekly administration
of cisplatin 40 mg m–2, 5-fluorouracil 500 mg m–2, epidoxorubicin 35 mg m–2, 6S stereoisomer of leucovorin 250 mg m–2 and glutathione
1.5 mg m–2, supported by a daily administration of lenograstim at a dose of 5 mg kg–1. Nineteen patients were men and three were women.
Median age was 63 years (range 47–70). At study entry, pain was present in 15 out of 22 patients (68%) with a mean value of
Scott–Huskisson scale of 27.6 ± 23.8, whereas a weight loss >10% was present in 15 patients. After eight weekly treatments, three partial
responses were achieved for a response rate of 13% (95% CI 0–26%), five patients had stable disease and 14 progressed on therapy. Pain
was present in 9 out of 22 patients (40%) with a mean value of Scott–Huskisson scale of 12.3 ± 18.4. Eight patients (36%) (three partial
response and five stable disease) had a positive weight change. Toxicity was mild: WHO grade III or IV toxicity was recorded in terms
of anaemia in 7 out of 188 cycles (3.7%), of neutropenia in 9 out of 188 cycles (4.7%) and of thrombocytopenia in 3 out of 188 cycles
(1.5%). Median survival of all patients was 6 months. The outcome of this intensive chemotherapy regimen does not support its use in
pancreatic cancer.
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The chemotherapeutic regimen consisted of a 1-day weekly
administration of CDDP 40 mg m—2 as a 30-min infusion in 250 ml
of normal saline solution, 5-FU 500 mg m—2 as a 15-min infusion
in 100 ml of normal saline solution, epi-ADR 35 mg m—2 by intra-
venous bolus. 6S stereoisomer of leucovorin was administered at a
dose of 250 mg m—2 diluted in 250 ml of normal saline solution in
a 4-h infusion concurrent with hydration.
Glutathione was given at a dose of 1.5 g m—2 in 100 ml of
normal saline over 15 min immediately before each CDDP admin-
istration to prevent CDDP-associated neurotoxicity, as indicated
by our previous experience (Cascinu et al, 1995). Standard
intravenous hydration was used: 2 h before initiation of the
CDDP infusion, patients were hydrated with 1500 ml of 0.9%
sodium chloride to which 20 mequiv. of potassium chloride and
15 mequiv. of magnesium sulphate were added. Post-hydration
was continued for 2 h with 1000 ml of normal saline solution. As
an antiemetic regimen, all patients received dexamethasone 20 mg
in 50 ml saline given as an intravenous infusion over 15 min, 45
min before CDDP, and ondansetron 8 mg made up to 50 ml saline
as an intravenous infusion over 15 min.
From the day before to the day after each chemotherapy admin-
istration, lenograstim was administered by subcutaneous injection
at a dose of 5 mg kg—1. One cycle of therapy consisted of eight
weekly treatments. Patients who showed responsive or stable
disease received a further 6 weeks of therapy. Full doses of anti-
cancer drugs were given if the leucocyte count was 4000 ml—1 and
if the platelet count was greater than 100 000 ml—1; when the leuco-
cyte and platelet counts were less than this, we delayed the treat-
ment by a week or until a complete recovery occurred. If grade 2
and 3 mucositis or diarrhoea occurred, treatment was delayed by a
week or until normalization. For grade 4 toxicities, patients were
removed from the study. No dose reductions were allowed.
Evaluation of response and toxicity
Response and toxicity evaluation was based on the World Health
Organization criteria (Miller et al, 1981), and on intention-to-treat
analysis. Evaluation of response was performed after 8 and 14
weekly treatments, although toxicity was evaluated weekly. Overall
incidence and intensity (Scott—Huskisson scale) of pain was
recorded at baseline and after 8 weeks, as well as weight changes.
Statistical methods
This was a multi-institutional phase II study; the primary objective
was to determine the response rate and the toxicity of the weekly
intensive chemotherapy. Secondary objectives were to measure
the palliation of symptoms and survival.
According to the optimal two-stage phase II design, the treat-
ment programme was designed to reject a response rate <30% (p0)
and to provide a statistical power of 90% in assessing the activity
of the regimen (in terms of response rate) as 45% (p1) (p1—p0 =
15%) for an alpha error less than 0.05 (Simon, 1989).
The 95% exact confidence interval (CI) for response was calcu-
lated. Survival time was calculated from the onset of chemo-
therapy. Chi-squared test with Yates correction and Wilcoxon test
were used to assess the difference of pain between baseline and
after eight chemotherapeutic treatments.
RESULTS
Investigators from six institutions treated 22 advanced pancreatic
cancer patients with this weekly intensive regimen. The study was
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Table 1 Patient characteristics
No. of patients 22
Age (years)
Median 63.5
Range 47–70
Sex
Men/Women 19/3
Performance status (ECOG)
02
I1 0
II 9
III 1
Disease at presentation
Locally advanced 4
Metastatic 16
Locally advanced and metastatic 2
Site of primary tumour
Head 7
Body 8
Tail 7
Histology
Well differentiated 15
Moderately differentiated 5
Poorly differentiated 2
Symptoms
Pain 15
Dyspepsia 9
Weight loss >10% 15
Table 2 Toxicity (WHO criteria): number of episodes for each administration (week 1–8)
Toxicity Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8
WHO grade 1 or 2/3 or 4 1 or 2/3 or 4 1 or 2/3 or 4 1 or 2/3 or 4 1 or 2/3 or 4 1 or 2/3 or 4 1 or 2/3 or 4 1 or 2/3 or 4
Leucopenia 3/– 4/– 6/1 3/2 6/1 5/– 2/1 4/1
Thrombocytopenia –/– 5/– 3/– 4/– 6/1 3/– 5/1 4/–
Anaemia 2/– 3/– 4/– 3/1 5/– 4/1 4/2 1/–
Mucositis –/– 1/1 –/1 2/1 –/– 1/– 2/– 1/–
Diarrhoea 1/– 2/– 2/1 1/– 2/– –/–\ 1/– 1/–
Nausea/vomiting 5/2 7/2 7/1 4/1 6/1 2/1 1/1 2/1
Neurotoxicity –/– –/– –/– 1/– –/– 2/– –/– –/–closed earlier because it was evident that the nine objective
responses, requested by the first stage of study, could not be
achieved even completing the enrolment of all the planned 27
patients. The median follow-up from the start of treatment was 18
months (range 11—26 months). The characteristics of treated
patients are detailed in Table 1.
Tumour response
All patients had measurable disease on computerized tomography
(CT) scan. Objective tumour response was seen in 3 out of 22
patients (13%, 95% CI 0—26%) with five patients showing stable
disease and 14 progressing on therapy. All responses were
obtained after the first 8 weeks.
Patient survival
The median survival time of all 22 patients was 6 months (range
3—15 months), with a 1-year survival rate of 13%.
Symptomatic effects
At baseline, pain was present in 15 out of 22 patients (68%), with
a mean Scott—Huskisson scale value of 27.6 ± 23.8. After 8 weeks,
pain was present in 9 out of 22 patients (40%) with a mean
Scott—Huskisson scale value of 12.3±18.4. The difference between
these mean values was statistically significant (P = 0.022). Eight
patients (36%) (three partial responses and five stable disease) had
a positive weight change after 8 weeks.
Toxicity
Eight patients did not complete the first 8 weeks of treatment:
three because of progressive disease and five because of toxicity
(neutropenia and/or thrombocytopenia). No patient received the
planned eight weekly treatments without some delay: in two
patients, it was for a week; in three, for 2 weeks; in three, for 3
weeks; in three, for 4 weeks; and in one, for 8 weeks.
Of the eight patients who received six further weekly treat-
ments, two did not complete the programme: one for progressive
disease and one for toxicity. Some delay in weekly treatment was
present in all the remaining six patients: in one patient, therapy
was delayed for a week; in one, for 2 weeks; in one for 3 weeks; in
two for 5 weeks; and in one for 8 weeks.
We did not observe any treatment-related death. Specific treat-
ment-related toxicities per cycle administered are detailed in Tables 2
and 3. There was no evidence of cumulative toxicity in the following
treatment weeks. The main common side-effect was leucopenia.
Non-haematological toxicities were uncommon and mild.
DISCUSSION
In advanced pancreatic cancer patients, the median survival is no
longer than 3—4 months, a figure which has not been significantly
influenced by chemotherapy during the last years (Ahlgren, 1996).
Nevertheless, recent studies have shown that chemotherapy can
improve overall survival compared with no treatment, without
impairing quality of life (Andr￿ et al, 1996; Glimelius et al, 1996;
Rothenberg et al, 1996; Burris et al, 1997). Consequently, attempts
to devise new chemotherapeutic regimens, with the aim of
improving response rates and survival, are justified. We assessed
in advanced pancreatic cancer the activity of a weekly regimen of
CDDP, epi-ADR, LV and 5-FU that has been shown effective in
advanced gastric cancer (Cascinu et al, 1997). The obtained
response rate (13%) as well as the median survival time of 6
months are not substantially better than those achieved with older
regimens such as FAM, FMS or 5-FU alone (Oster et al, 1986;
Schnall and Macdonald, 1996). Furthermore, our results are
similar to those obtained by Glimelius et al (1996) in the treatment
arm of the randomized trial compared with best supportive care,
but with a less toxic and expensive regimen.
Recently, comparable disappointing results were reported with
another intensive regimen particularly active in advanced gastric
cancer (Webb et al, 1997). ECF (epirubicin, cisplatin, 5-fluoro-
uracil), in fact, showed a response rate of 17%, with a considerable
toxicity that discourages its indiscriminate use highlighting the
need for a careful selection of patients (Evans et al, 1996).
In pancreatic cancer, the notoriously difficult determination of
objective response and the poor clinical conditions of several
patients may account for the modest results achievable even by
using intensive chemotherapeutic regimens. In fact, in pancreatic
tumours, there is an important desmoplastic reaction induced by
the tumour including inflammation and fibrosis within and around
the tumour. Because this tissue does not necessarily shrink after
chemotherapy, the size of the tumour on a CT scan may not reflect
the true proportion of tumour response. Thus, the use of locally
advanced pancreatic cancer as the sole indicator of response may
yield misleading results (Ahlgren, 1996). In contrast, although
metastatic lesions contain less desmoplastic component, advanced
disease is associated with poor performance status and/or compli-
cations which can limit patient tolerance for chemotherapy, espe-
cially for aggressive regimens (Casper and Kelsen, 1995).
In our study, a favourable aspect was the presence of sympto-
matic effects, particularly a reduction in pain. After eight weekly
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Table 3 Toxicity (WHO criteria): number of episodes for each administration (week 9–14)
Toxicity Week 9 Week 10 Week 11 Week 12 Week 13 Week 14
WHO grade 1 or 2/3 or 4 1 or 2/3 or 4 1 or 2/3 or 4 1 or 2/3 or 4 1 or 2/3 or 4 1 or 2/3 or 4
Leucopenia 1/– 3/1 4/1 1/1 3/– 1/–
Thrombocytopenia 1/– 4/1 3/– 2/– 1/– 3/–
Anaemia 4/1 3/– 4/– 3/1 2/1 3/–
Mucositis 2/1 –/– –/1 1/– –/– –/–
Diarrhoea 1/– –/– 2/– –/– –/– –/–
Nausea/vomiting 2/1 1/– 1/– 1/– 1/– 1/–
Neurotoxicity –/– –/– –/– 1/– –/– 2/–treatments, pain was present in 40% of patients compared with
68% at baseline, with a significant reduction in intensity as
expressed by Scott—Huskisson scale values. However, in other
clinical trials using less aggressive regimens, chemotherapy was
found to improve quality of life and performance status (Andr￿ et
al, 1996; Glimelius et al, 1996). In particular, gemcitabine showed
a very favourable toxicity profile and has demonstrated activity in
this disease. Response rates ranged from 10% to 15% and the
treatment reduced symptoms caused by the cancer in 20—30% of
patients (Carmichael et al, 1995; Moore, 1996). A randomized trial
comparing gemcitabine with 5-FU showed a significant improve-
ment in clinical benefit (24% compared with 5%), as well as a
significantly longer survival in patients receiving gemcitabine
(Burris et al, 1997).
As in our case, subjective improvements observed in clinical
trials were greater than expected from the tumour objective
response rates. This can be due to the difficulty in properly quanti-
fying objective response in this tumour, as discussed above. This
being the case, the assessment of clinical benefit represents a new
field of investigation in evaluating the activity and the role of
chemotherapy in pancreatic cancer (Rothenberg et al, 1996). There
is general acceptance that this new treatment end point needs to be
explored in addition to classical end points (objective response and
survival) in future chemotherapy trials in this disease.
In conclusion, the outcome of our intensive chemotherapy
regimen does not support its use in advanced pancreatic cancer.
Other drugs or regimens, achieving similar clinical benefit and
survival, seem to be more convenient in terms of both economic
aspects and patient￿s compliance.
REFERENCES
Ahlgren JD (1996) Chemotherapy for pancreatic cancer. Cancer 78: 654—663
Andr￿ T, Lotz JP, Bouleuc C, Azzoust K, Houry S, Hannoun L, See J, Steso A,
Avenin D and Izrael V (1996) Phase II trial of 5-fluorouracil, leucovorin and
cisplatin for treatment of advanced pancreatic adenocarcinoma. Ann Oncol 7:
173—178
Burris MA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR,
Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA,
Stephens CD and Von Hoff DD (1997) Improvement in survival and clinical
benefit with gemcitabine as first-line therapy for patients with advanced
pancreatic cancer: a randomized trial. J Clin Oncol 15: 2403—2413
Carmichael J, Fink U, Russel RCG, Spittle MF, Harris A and Spiessl G (1995) Phase
II study of gemcitabine in patients with advanced pancreatic cancer. Br J
Cancer 73: 101—105
Cascinu S, Cordella L, Del Ferro E, Fronzoni M and Catalano G (1995)
Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy
in advanced gastric cancer: a randomized double-blind placebo-controlled trial.
J Clin Oncol 13: 26—32
Cascinu S, Labianca R, Alessandroni P, Marcellini M, Silva RR, Pancera G, Testa E,
Martignoni G, Barni S, Frontini L, Zaniboni A, Luporini G, Cellerino R and
Catalano G (1997) Intensive weekly chemotherapy for advanced gastric cancer
using 5-fluorouracil, cisplatin, epidoxorubicin, 6S-leucovorin, glutathione and
filgrastim. A report from the Italian Group for the Study of Digestive Tract
Cancer (GISCAD). J Clin Oncol 5: 3313—3319
Casper ES and Kelsen DP (1995) Adenocarcinoma of the pancreas: overview of
workup and management. Adv Oncol 11: 17—22
Cocconi G, Bella M, Zironi S, Algeri R, Di Costanzo F, De Lisi G, Luppi G,
Mazzocchi B, Rodino￿ C, Soldani M, Gilli G and Finardi C (1994)
Fluorouracil, doxorubicin and mitomycin combination versus PELF
chemotherapy in advanced gastric cancer: a prospective randomized trial of the
Italian Oncology Group for Clinical Research. J Clin Oncol 12: 2687—2693
Evans TRJ, Lofts FJ, Mansi JL, Gless JP, Dalgleish AG and Knight MJ (1996) A
phase II study of continuous-infusion 5-fluorouracil with cisplatin and
epirubicin in inoperable pancreatic cancer. Br J Cancer 73: 1620—1624
Glimelius B, Hoffman K, Sjoden PO, Jacobsson G, Sellstrom H, Enander LK, Linne
T and Svensson C (1996) Chemotherapy improves survival and quality of life
in advanced pancreatic and biliary cancer. Ann Oncol 7: 593—600
Kelly DM and Benjamin IS (1995) Pancreatic cancer. Ann Oncol 6: 19—28
Lionetto R, Pugliese V, Bruzzi P and Rosso R (1995) No standard treatment is
available for advanced pancreatic cancer. Eur J Cancer 31A: 882—887
Moore M (1996) Activity of gemcitabine in patients with advanced pancreatic
carcinoma. A review. Cancer 78: 633—638
Miller AB, Hoodgstraten B, Staquet M and Winkler A (1981) Reporting results of
cancer treatment. Cancer 47: 207—214
Oster MW, Gray R, Panasci L and Perry MC (1986) Chemotherapy for advanced
pancreatic cancer: a comparison of 5-fluorouracil, adriamycin, and mitomycin-
c (FAM) with 5-fluorouracil, streptozotocin and mitomycin-c (FSM). Cancer
57: 29—33
Palmer KR, Kerr M, Knowles G, Cull A, Carter DC and Leonard RC (1994)
Chemotherapy prolongs survival in inoperable pancreatic cancer. Br J Surg 81:
882—885
Rothenberg ML, Abruzzese JL, Moore MJ, Robertson JM and Wanebo HJ (1996) A
rationale for expanding the end-points for clinical trials in advanced pancreatic
carcinoma. Cancer 78: 627—632
Schnall S and Macdonald JS (1996) Chemotherapy of adenocarcinoma of the
pancreas. Semin Oncol 23: 220—228
Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin
Trials 10: 1—10
Taylor I (1993) Should further studies of chemotherapy be carried out in pancreatic
cancer? Eur J Cancer 29A: 1076—1078
Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M,
Mansi J, Findlsy M, Hill A, Oates J, Nicolson M, Hickish T, O￿Brien M,
Iveson T, Watson M, Underhill C, Wardley A and Meehan M (1997)
Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus
fluorouracil, doxorubicin and methotrexate in advanced oesophago-gastric
cancer. J Clin Oncol 15: 261—267
494 S Cascinu et al
British Journal of Cancer (1999) 79(3/4), 491–494 © Cancer Research Campaign 1999